InvestorsHub Logo

hoffmann6383

03/09/22 12:58 PM

#449945 RE: hyperopia #449943

Thanks for sharing Hyperopia. Some good info here.

sukus

03/09/22 1:09 PM

#449957 RE: hyperopia #449943

Very nice of you sharing this important info about potential capacity Hyperopia.

flipper44

03/09/22 1:12 PM

#449962 RE: hyperopia #449943

Great additional comparison info. Thanks.

ATLnsider

03/09/22 1:53 PM

#449977 RE: hyperopia #449943

hyperopia, I appreciate your analysis of potential DCVax-L production capacity at Sawston. But, I do have a few questions for you:

Since the Kite facility is producing CAR-T therapies, and the production process for producing autologous dendritic cell therapies is different, would it make more sense to take what NWBio said about the current cold room production capacity, with only about 1/6 of Sawston built-out, is about 400 to 500 patients per year. Then, Flaskworks would increase that production capacity by 10x, up to 4,000 to 5,000 patients per year.

Then, if all of Sawston was built out (6/6 vs only 1/6) and is using Flaskworks, we could scale the production capacity up to 24,000 to 30,000 patients per year.

What do you think?

Dr Bala

03/09/22 2:01 PM

#449978 RE: hyperopia #449943

Decent. Thanks, hyperopia.

sentiment_stocks

03/09/22 2:45 PM

#449990 RE: hyperopia #449943

As an aside, looking at the sub-lease agreement, it seems that about 35% (2560 sq ft) of the "unfinished and/or un-equipped interior space (7884 sq ft) will be for the Nitrogen cryostorage area.

I'd think at least some part of that area would be intended for tumor storage for Northwest purposes?

https://www.sec.gov/Archives/edgar/data/1072379/000141057822000244/nwbo-20211231xex10d87.htm